NTRK IHC • FISH • NGS Breadcrumb Home NTRK Make NTRK gene fusion testing part of your patient care. There are various methodologies to test for neurotrophic tropomyosin receptor kinase (NTRK) gene fusion, including immunohistochemistry (IHC), FISH, and RNA Fusion by next-generation sequencing (NGS). Testing for NTRK gene fusions is essential to identify patients that harbor the genomic alterations who are now eligible for therapy that may ultimately address their cancer. It has been shown that patients with tumors driven by these gene rearrangements are excellent candidates for targeted tyrosine kinase receptor (TRK) inhibitors for locally advanced or metastatic solid tumors with NTRK fusions. NTRK gene fusion frequency1 NTRK gene fusions are a class of oncogenes associated with a wide range of pediatric and adult solid tumors.2 These genomic alterations may lead to TRK fusion proteins that are mutually exclusive oncogenic drivers that have been associated with more aggressive cancer in some tumor types.2-4 IHC FISH RNA FUSIONS BY NGS Inexpensive methodology Rapid turnaround time Location of the target within the cell is visible7,8 High sensitivity and specificity8 Detection of novel fusion partners (depending on method)10 Ability to interrogate multiple genomic alterations simultaneously10 Growing relevance as NGS can accurately detect many genomic alterations in therapeutically relevant cancer genes in a single assay5,6 Detects both fusion and wild type TRK expression5 Not all neoplasms are appropriate for IHC screening Pan-TRK IHC lacks the specificity required for a definitive, stand-alone assay6 Requires fluorescence microscopy8 Target sequence must be known (break-apart FISH may detect NTRK gene fusions with unknown partners, but both in-frame and out-of-frame fusions will be detected)10 Some intra-chromosomal fusions may not be detected Turnaround time is generally longer than other methodologies LEARN MORE LEARN MORE LEARN MORE References: Hsiao, Susan J., et al. (2019) Jour Molec Diag. Stransky N, et al. Nat Commun. 2014;5:846. Park DY, et al. Oncotarget. 2015;7(7):8399-8412. Vaishnavi A, et al. Cancer Discov. 2015;5:25-34. Bourgeois JM et al. Am J Surg Pathol. 2000;24:937-946 Murphy D. et al Appl lmmunohistochem Mol Morphol 2017:25:513-523. Kerr KM, Lopez-Rios F. Ann Oncol. 2016;27:iii16-iiii24. Cui C. et al. Front Cell Dev Biol. 2016;4:89 Chae YK, et al Oncotarget. 2017;8:100863-100898. Church AJ, et al. Mod Pathol. 2018;31:463-473. Main navigation Diagnostic Services Pharma Services Data Services Inivata Patients Test Menu CONTACT US 9490 NeoGenomics Way Fort Myers, FL 33912 T: 239.768.0600 F: 239.690.4237 Glassdoor Icon Linkedin Icon Twitter Icon YouTube Icon MORE FROM NEO InVisionFirst®-Lung Lung Cancer Awareness Biomarker Assist™ KRAS SGT PIK3CA Mutation CDx Thyroid Testing Program NTRK NEONEWS SIGN UP Receive weekly updates on NeoGenomics tests, research, events, and publications. First Name last Name Email One Lab. Vital Answers. Transforming Care for Cancer Patients. Footer Utility Client Services About Billing Contact Careers NeoLink Login Copyright © 2021 NeoGenomics Laboratories. All rights Reserved. Privacy. Terms. Licensing. Do not sell my personal information. Contact Form Toggle Patients Patients - 4760 Test Menu Header Utility Client Services Client Services - 2359 About About - 6043 Billing Billing - 9576 Careers Contact NeoLINK Login We use cookies on this site to enhance your user experience By clicking the Accept button, you agree to us doing so. More info OK, I agree